CryoLife is the market leader in vascular allografts with over 49 published clinical studies, dedicated Representatives, and professional educational programs that train fellows and residents. CryoLife is accredited by the American Association of Tissue Banks (AATB) and meets all FDA and state tissue processing requirements.

Since 1986, over 84,000 CryoLife CryoVein and CryoArtery cryopreserved human vascular allografts have been implanted to treat a variety of vascular reconstructions such as peripheral bypass, hemodialysis access, and aortic infections which have saved the lives and limbs of patients.